antibody-drug conjugates
- Health
Iksuda Therapeutics Enters License Agreement With University of Goettingen to Develop a New Generation of Antibody Drug Conjugates
Newcastle, England: Iksuda licenses novel protein-alkylating, tumour-activated pro-drug payload series to develop ADCs with enhanced therapeutic index Development to focus…
Read More » - World
Synaffix Wins Best Platform Technology at 7th Annual World ADC Awards
Amsterdam, Netherlands: Synaffix B.V., a biotechnology company enabling antibody-drug conjugates (ADCs) with best-in-class therapeutic index, announces that it has won…
Read More » - Business
Synaffix Sees Competitive Early In Vivo Data from ADCs Based on Proprietary Exatecan Linker-Payload
Amsterdam, Netherlands: In vivo efficacy on a par with gold standard deruxtecan-based ADCs Poster to be presented at World ADC…
Read More »